Mechanisms of Drug Interactions

Mechanisms of Drug Interactions

Mechanisms of Drug Interactions

On this page

Mechanisms: Overview - Med Mixology 101

  • Drug Interaction (DI): Drug's effect modified by another substance (drug, food, herb).
  • Primary Mechanisms:
    • Pharmacokinetic (PK): Body's action on drug altered ("ADME").
      • Absorption: e.g., Chelation, pH changes.
      • Distribution: Protein binding displacement.
      • Metabolism: CYP450 enzyme induction/inhibition.
      • Excretion: Altered renal/biliary clearance.
    • Pharmacodynamic (PD): Drug's action on body modified.
      • Receptor interactions (synergism, antagonism).
      • Post-receptor effects.
    • Pharmaceutical: Physical/chemical incompatibility (e.g., IV admixtures).
  • Key Outcomes: ↑Toxicity or ↓Efficacy.

⭐ Most clinically significant drug interactions involve alterations in drug metabolism via CYP450 enzyme induction or inhibition (Pharmacokinetic).

Mechanisms: PK (AD) - Entry & Spread Sabotage

  • Absorption (Entry Sabotage)
    • Altered Gastric pH:
      • Antacids (↑pH) ↓ absorption of acidic drugs (e.g., ketoconazole, iron).
      • Acidic environment (stomach) favors acidic drug absorption.
    • Chelation/Complexation:
      • Tetracyclines, Fluoroquinolones + Ca²⁺, Mg²⁺, Fe²⁺/³⁺, Al³⁺ (in antacids, dairy, iron preps) → ↓ absorption. 📌 "TFs bind Cations" (Tetracyclines, Fluoroquinolones bind Cations).
    • Altered Gut Motility:
      • Prokinetics (e.g., metoclopramide): ↑ motility → ↓ absorption of slowly absorbed drugs (e.g., digoxin); ↑ for rapidly absorbed (e.g., paracetamol).
      • Anticholinergics: ↓ motility → opposite effects.
    • P-glycoprotein (P-gp) Efflux Pump Modulation:
      • Inducers (e.g., rifampicin): ↑ P-gp efflux → ↓ absorption of substrates (e.g., digoxin).
      • Inhibitors (e.g., verapamil): ↓ P-gp efflux → ↑ absorption of substrates (e.g., digoxin).
  • Distribution (Spread Sabotage)
    • Protein Binding Displacement:
      • Highly protein-bound drugs (e.g., warfarin, phenytoin, sulfonamides) can displace each other from albumin.
      • Aspirin displaces warfarin → ↑ free warfarin → ↑ bleeding risk.
      • ⭐ > Displacement is clinically significant mainly for drugs with >90% protein binding, small Volume of Distribution (Vd), and narrow therapeutic index.
    • Altered Tissue Uptake/Binding:
      • Digoxin + Quinidine: Quinidine displaces digoxin from tissue binding sites & inhibits P-gp → ↑ plasma digoxin levels → toxicity.

Mechanisms: PK (ME) - Metabolism & Exit Mayhem

Metabolism (Biotransformation): Primarily hepatic; alters drug structure.

  • Enzyme Induction: ↑Metabolism. Effect: ↓Drug levels/failure or ↑Toxic metabolite. Onset: Slow.
    • 📌 Inducers: CRAP GPS (Carbamazepine, Rifampicin, Alcohol (chronic), Phenytoin, Griseofulvin, Phenobarbitone, Sulfonylureas/Smoking/St. John's Wort).
  • Enzyme Inhibition: ↓Metabolism. Effect: ↑Drug levels/toxicity. Onset: Rapid.
    • 📌 Inhibitors: SICKFACES.COM Group (Sodium valproate, Isoniazid, Cimetidine, Ketoconazole, Fluconazole, Alcohol (acute), Chloramphenicol, Erythromycin, Sulfonamides, Ciprofloxacin, Omeprazole, Metronidazole, Grapefruit juice).
  • CYP450: Main system; CYP3A4 for ~50% drugs. Genetic variants (CYP2D6, CYP2C19) → varied response.
Loading diagram…

⭐ Grapefruit juice (CYP3A4 inhibitor) ↑ levels & toxicity of statins, Calcium channel blockers, cyclosporine.

Excretion (Elimination): Primarily renal.

  • Renal:
    • Filtration: unbound drug.
    • Secretion: active; competition (Probenecid + Penicillin → ↑Penicillin).
    • Reabsorption: pH-dependent ion trapping.
      • Acidic drugs (Aspirin): Alkalinize urine (NaHCO₃) for ↑Excretion.
      • Basic drugs (Amphetamine): Acidify urine (NH₄Cl) for ↑Excretion.
  • Biliary & Enterohepatic Circulation:
    • Bile excretion, gut reabsorption → prolongs action (Digoxin, OCPs).
    • Antibiotics may ↓ OCP efficacy.

Mechanisms: PD - Target Site Tussles

  • Drugs interact at same/related target sites, altering cellular/physiological response.
  • Receptor Site Competition:
    • Competitive Antagonism: Naloxone (antagonist) displaces morphine (agonist) at µ-opioid receptors.
    • Partial vs. Full Agonist: Buprenorphine (partial agonist) can ↓ efficacy of morphine (full agonist) if co-administered.
  • Allosteric Modulation:
    • Drugs bind to different sites on one receptor complex, modifying the primary ligand's effect.
    • E.g., Benzodiazepines & Barbiturates on GABA-A receptor (enhance GABAergic inhibition, ↑Cl⁻ influx).
  • Physiological (Functional) Antagonism:
    • Two drugs act on different receptors/pathways, producing opposing physiological effects on the same system.
    • E.g., Histamine (H1; bronchoconstriction) vs. Adrenaline (β2; bronchodilation).

⭐ Co-administration of Sumatriptan (5-HT1D agonist) and Ergotamine derivatives is contraindicated due to synergistic vasoconstriction (risk of severe coronary/cerebral ischemia); allow at least a 24-hour interval between them.

High‑Yield Points - ⚡ Biggest Takeaways

  • Pharmacokinetic (PK) interactions alter drug ADME (Absorption, Distribution, Metabolism, Excretion).
  • Pharmacodynamic (PD) interactions at target sites: synergism, antagonism, additive effects.
  • CYP450 enzyme induction (e.g., rifampicin) ↓ drug levels, reducing efficacy.
  • CYP450 enzyme inhibition (e.g., ketoconazole) ↑ drug levels, increasing toxicity risk.
  • P-glycoprotein (P-gp) modulation impacts drug absorption and cellular efflux.
  • Altered absorption: chelation (e.g., tetracyclines + antacids) or pH changes reduce bioavailability.
  • Protein binding displacement (e.g., warfarin by NSAIDs) ↑ free drug concentration and effect.

Unlock the full lesson and continue reading

Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more

Scan to download app

Scan to download
UNLOCK FREE ACCESS

Practice Questions: Mechanisms of Drug Interactions

  1. 1. Which concurrent medication carries the greatest risk of serious bleeding when aspirin is added?

    • A. Oral contraceptives
    • B. Warfarin sodium
    • C. Prednisolone
    • D. Theophylline
    Show answer

    Answer: B. Warfarin sodium

    Warfarin sodium Warfarin carries the greatest serious bleeding risk among these options when combined with aspirin because anticoagulation and platelet inhibition impair different components of hemostasis. Aspirin also causes gastrointestinal mucosal injury. The combination is generally avoided unless specifically indicated, but it is not universally contraindicated. Prednisolone - Prednisolone and aspirin can both increase gastrointestinal injury and peptic-ulcer risk, but this combination is not generally an absolute contraindication. - When clinically necessary, they may be coadministered with measures such as proton-pump inhibitor prophylaxis and monitoring for gastrointestinal complications. Theophylline - Aspirin does not produce a clinically important interaction with theophylline metabolism or clearance, so it does not create the characteristic major bleeding risk seen with warfarin. - Although toxicity monitoring may be needed for theophylline, aspirin treatment is not generally contraindicated solely because the patient is receiving theophylline. Oral contraceptives - There is no major direct contraindication between aspirin and oral contraceptives based on a clinically significant pharmacokinetic interaction. - Oral contraceptives increase thrombotic tendency, whereas aspirin has antiplatelet activity; this contrast does not produce the dangerous additive hemorrhage seen with warfarin.

  2. 2. In a 70-kg adult, a drug has an apparent volume of distribution of 60 L. What does this indicate about the drug's distribution?

    • A. Predominant plasma protein binding
    • B. Extracellular fluid confinement
    • C. Substantial tissue binding
    • D. Uniform total-body-water distribution
    Show answer

    Answer: C. Substantial tissue binding

    Substantial tissue binding can raise apparent Vd beyond the approximately 42-L total body water in a 70-kg adult, explaining the Vd of 60 L. Predominant plasma protein binding tends to lower Vd by retaining drug in plasma rather than accounting for a Vd of 60 L. Extracellular fluid confinement corresponds to a Vd of about 14 L in a 70-kg adult, not 60 L. Uniform total-body-water distribution corresponds to a Vd of about 42 L in a 70-kg adult, not 60 L.

  3. 3. A patient with a previously stable INR on warfarin develops a sustained INR increase several weeks after starting one additional drug. Which drug is the most likely cause?

    • A. Amiodarone
    • B. Phenytoin
    • C. Carbamazepine
    • D. Rifampicin
    Show answer

    Answer: A. Amiodarone

    Amiodarone - Amiodarone is a well-known inhibitor of CYP2C9, the primary enzyme responsible for the metabolism of S-warfarin, the more potent enantiomer of warfarin. - Inhibition of warfarin metabolism leads to increased warfarin levels, thereby enhancing its anticoagulant effect and causing a higher INR. Phenytoin has a biphasic interaction with warfarin: INR may initially rise, whereas established enzyme induction generally lowers INR. Phenytoin is therefore not the expected cause of a sustained INR increase several weeks after initiation. Carbamazepine - Carbamazepine is a potent enzyme inducer, particularly of CYP3A4 and CYP2C9. - Like phenytoin, it generally leads to increased warfarin metabolism and a reduced INR, thereby decreasing its anticoagulant efficacy. Rifampicin - Rifampicin is a strong inducer of hepatic cytochrome P450 enzymes, especially CYP3A4 and CYP2C9. - Its co-administration with warfarin significantly increases warfarin metabolism, resulting in lower warfarin concentrations and a decreased INR.

  4. 4. For a drug administered orally with bioavailability F = 0.5, which statement is FALSE?

    • A. Loading dose: Vd × target concentration
    • B. First-order elimination: constant half-life
    • C. Lipid solubility: increased drug distribution into tissues
    • D. Plasma protein binding: reduced distribution
    Show answer

    Answer: A. Loading dose: Vd × target concentration

    Loading dose: Vd × target concentration is false here because the administered oral loading dose must be divided by F, which is 0.5. First-order elimination: constant half-life is correct because a constant fraction is eliminated per unit time. Lipid solubility: increased drug distribution into tissues describes the usual tendency of lipid-soluble drugs to enter tissues. Plasma protein binding: reduced distribution describes the effect of retaining drug in plasma, other factors being equal.

  5. 5. A 32-year-old woman taking warfarin develops prolonged menstrual bleeding after starting another drug. Which drug is least likely to potentiate warfarin-associated bleeding?

    • A. Co-trimoxazole
    • B. Carbamazepine
    • C. Ciprofloxacin
    • D. Clarithromycin
    Show answer

    Answer: B. Carbamazepine

    Carbamazepine - Carbamazepine is a potent CYP enzyme inducer that accelerates warfarin metabolism, lowering plasma warfarin concentrations and reducing its anticoagulant effect. - Because it tends to decrease INR and may increase thrombotic risk, it is least likely among these options to cause or exacerbate warfarin-associated bleeding. Co-trimoxazole - Co-trimoxazole can potentiate warfarin because sulfamethoxazole inhibits CYP2C9-mediated metabolism of S-warfarin, increasing INR and bleeding risk. Ciprofloxacin - Ciprofloxacin can inhibit warfarin metabolism, including through effects on CYP1A2, reducing warfarin clearance and increasing anticoagulant exposure. - This interaction may raise the INR and increase bleeding risk, so ciprofloxacin is not the least-likely interacting medication. Clarithromycin - Clarithromycin, a macrolide, inhibits CYP3A4 and can reduce warfarin metabolism, increasing its concentration and anticoagulant effect. - The resulting INR elevation can worsen prolonged vaginal bleeding, making clarithromycin an unsuitable answer to the least-likely-interaction question.

  6. 6. Assuming unchanged tissue binding, increased plasma protein binding is associated with which property?

    • A. Increased glomerular filtration
    • B. Less drug interaction
    • C. Less tubular secretion
    • D. Lower distribution volume
    Show answer

    Answer: D. Lower distribution volume

    Lower distribution volume - Highly protein-bound drugs remain largely within the vascular compartment, limiting their distribution from plasma into tissues. - Restricted tissue distribution produces a smaller apparent volume of distribution, making this the characteristic property of high plasma protein binding. Increased glomerular filtration - Increased glomerular filtration is incorrect because protein-bound drug is not freely filtered; greater binding reduces the fraction available for filtration. Less drug interaction - High plasma protein binding can increase the risk of drug interactions when another drug displaces the bound drug from albumin or other binding sites. - Displacement increases the free drug fraction, potentially enhancing pharmacological effects or causing toxicity rather than reducing interactions. Less tubular secretion - Plasma protein binding does not inherently reduce tubular secretion, because the drug can dissociate from protein and become available to secretory transporters. - Many highly protein-bound drugs undergo substantial active secretion, with binding helping maintain delivery of free drug to the renal tubule.

  7. 7. Which is correct about the image shown below?

    • A. $X=$ Glutathione Reductase, $Y=$ Glutathione Peroxidase
    • B. $X=$ Glutathione peroxidase, $Y=$ Glutathione Reductase
    • C. $X=$ Superoxide Dismutase, $Y=$ Glutathione Reductase
    • D. $X=$ Glutathione Reductase, $Y=$ Superoxide Dismutase
    Show answer

    Answer: B. $X=$ Glutathione peroxidase, $Y=$ Glutathione Reductase

    $X=$ Glutathione peroxidase, $Y=$ Glutathione Reductase - Glutathione peroxidase catalyzes the reduction of hydrogen peroxide to water using 2GSH, identifying X as glutathione peroxidase. - Glutathione reductase regenerates reduced glutathione from oxidized glutathione using NADPH + H⁺, identifying Y as glutathione reductase. $X=$ Glutathione Reductase, $Y=$ Glutathione Peroxidase - This reverses the enzyme assignments: glutathione reductase reduces oxidized glutathione rather than detoxifying hydrogen peroxide. - Glutathione peroxidase removes hydrogen peroxide, whereas glutathione reductase regenerates reduced glutathione; therefore X and Y are incorrectly assigned. $X=$ Superoxide Dismutase, $Y=$ Glutathione Reductase - Superoxide dismutase converts superoxide to hydrogen peroxide, so it does not perform the peroxide-detoxifying reaction attributed to X. - Although glutathione reductase correctly describes Y, the incorrect identification of X makes this option false. $X=$ Glutathione Reductase, $Y=$ Superoxide Dismutase - X is not glutathione reductase, because X acts on hydrogen peroxide rather than regenerating reduced glutathione from oxidized glutathione. - Y is not superoxide dismutase; Y participates in the glutathione cycle by regenerating reduced glutathione.

  8. 8. The release of histamine and leukotrienes from mast cells is prevented by which of the following drugs?

    • A. Zileuton
    • B. Fexofenadine
    • C. Nedocromil
    • D. Zafirlukast
    Show answer

    Answer: C. Nedocromil

    Nedocromil - Nedocromil stabilizes sensitized mast cells and inhibits their degranulation after IgE–antigen interaction. - By preventing the calcium-dependent degranulation process, it reduces release of histamine, leukotrienes, and prostaglandins. Zileuton - Zileuton inhibits 5-lipoxygenase, reducing leukotriene synthesis from arachidonic acid rather than preventing mast-cell degranulation. - It does not block the release of preformed histamine from mast cells, so it does not fit the stated mechanism. Fexofenadine - Fexofenadine is a second-generation H₁ antihistamine that blocks histamine effects at its receptor. - It does not prevent mast-cell mediator release and therefore cannot inhibit the release of histamine and leukotrienes. Zafirlukast - Zafirlukast is a cysteinyl leukotriene receptor antagonist that blocks CysLT₁ receptors. - It inhibits the effects of leukotrienes at target tissues but does not prevent mast-cell release of leukotrienes or histamine.

  9. 9. At 12 hours after intravenous administration of a bolus dose, the plasma level of a drug is 3 mg/L. If the volume of distribution (Vd) is 10 L and the elimination half-life is 6 hours, what was the dose administered?

    • A. 180 mg
    • B. 120 mg
    • C. 480 mg
    • D. 240 mg
    Show answer

    Answer: B. 120 mg

    120 mg - The elapsed 12 hours represents two half-lives of 6 hours, so the initial concentration was four times 3 mg/L, or 12 mg/L. - Using the dose equation Dose = Vd × C0, the dose is 10 L × 12 mg/L = 120 mg. 180 mg - 180 mg does not account for the two completed half-lives between administration and measurement; reversing the decay from 3 mg/L gives an initial concentration of 12 mg/L. - With a 10 L volume of distribution, an initial concentration of 12 mg/L requires 120 mg, not 180 mg. 480 mg - 480 mg would imply an initial concentration of 48 mg/L with a 10 L volume of distribution, which is inconsistent with two half-lives of elimination. - After two half-lives, concentration decreases to one-quarter of its initial value; therefore, 3 mg/L corresponds to 12 mg/L initially, not 48 mg/L. 240 mg - 240 mg would correspond to an initial concentration of 24 mg/L in a 10 L volume of distribution, exceeding the concentration inferred from the stated half-life. - The drug has undergone only two half-lives in 12 hours, so the measured 3 mg/L must be multiplied by four, yielding a 120 mg dose.

  10. 10. Which combination increases atorvastatin-associated myotoxicity through strong CYP3A4 inhibition?

    • A. Phenytoin + atorvastatin
    • B. Itraconazole + atorvastatin
    • C. Amiodarone + atorvastatin
    • D. Carbamazepine + atorvastatin
    Show answer

    Answer: B. Itraconazole + atorvastatin

    Itraconazole + atorvastatin is the correct combination because itraconazole strongly inhibits CYP3A4 and increases atorvastatin exposure and myopathy risk. Phenytoin + atorvastatin instead involves enzyme induction, which can reduce atorvastatin exposure. Amiodarone + atorvastatin can increase exposure, but amiodarone is not a strong CYP3A4 inhibitor like itraconazole. Carbamazepine + atorvastatin involves CYP3A4 induction and can reduce atorvastatin exposure.

Flashcards: Mechanisms of Drug Interactions

  1. 1. Metoclopramide has drug interactions with _____ and _____ agents

    Show answer

    digoxin · diabetic

  2. 2. Simeprevir is an _____ of _____ and thus may have many drug interactions

    Show answer

    inhibitor · cytochrome P450

  3. 3. The H2 receptor antagonist _____ is a potent _____ of _____ and therefore has multiple drug interactions

    Show answer

    cimetidine · inhibitor · cytochrome P-450

  4. 4. _____ serves as both substrate and inhibitor for CYP_____.

    Show answer

    Omeprazole · 2C19

  5. 5. Drug antagonism between heparin and protamine sulfate is an example of  antagonism.

    Show answer

    chemical

  6. 6. Cardiovascular (Antiarrhythmics) _____, a class III antiarrhythmic, is an _____ of _____ and thus may have many drug interactions

    Show answer

    Amiodarone · inhibitor · cytochrome P450

  7. 7. Which one of the following drugs is a cytochrome p450 inducer? _____

    Show answer

    Rifampin

  8. 8. route of administration of Ty21a vaccine is _____

    Show answer

    oral — reacts with anti malarial antibiotics

  9. 9. Barbiturates are an _____ of _____ and thus may have many drug interactions

    Show answer

    inducer · cytochrome P450

Everything you need for Indian Medical PG prep

Get full Oncourse access with lessons, practice questions, flashcards and AI study tools.

GET STARTED FOR FREE
75% OFFLimited time offer
GET 75% OFF